BioSpace News Archive

Haemonetics Corporation, a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, announced that it has entered into a definitive agreement to sell its Fajardo, Puerto Rico, manufacturing operations to GVS, S.p.A, a leading provider of advanced filtration solutions for critical applications.

Tonix Pharmaceuticals Holding Corp. announced that Company management will participate and host one-on-one meetings at two virtual investor conferences in June.

Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present at the Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020 at 9:40 a.m. ET. The conference will be held in a virtual meeting format. Webcast information for this event will

Replimune Group, Inc. announced new interim data presented from the Phase 2 part of its Phase 1/2 clinical trial of RP1 in combination with Opdivo® that continues to provide strong support for its lead indications of cutaneous squamous cell carcinoma and anti-PD-1 refractory melanoma.

KeySource™ has earned Drug Distributor reaccreditation from the National Association of Boards of Pharmacy® for another three-year term.

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company targeting to revolutionize life-science product development across several market segments, announced today its participation in the CRISPR-IL consortium

International medical imaging IT and cybersecurity company Sectra reports the best earnings year in its history, exceeding its three financial goals.

Isofol Medical AB fully guaranteed new share issue with preferential rights for the Company’s existing shareholders, which ended on June 1, 2020, was oversubscribed.

Smith+Nephew, the global medical technology business, announced the publication of new clinical evidence further validating the exceptional performance of its proprietary OXINIUM - Oxidized Zirconium - on XLPE for total hip arthroplasty.

Shorla Pharma Limited, an Irish specialty pharmaceutical company, has announced the completion of a Series A investment of $8.3 million.